Brief news reports on Tuberculosis

India initiates process to develop national Essential Diagnostics List

The National Essential Medication List (EML) in India has been helpful in capping prices of a variety of products, and has increased access to important medicines. For the next step, a smaller working group will be created by the government, to move forward with the EDL process, which is expected to be completed by the end of the year.

Read More →

Unitaid: Online consultation on TB

Unitaid is seeking concrete, high-level suggestions and ideas on possible solutions to overcome challenges in tuberculosis that would be a good fit for the Unitaid strategy and operating model. As part of this online consultation, Unitaid will host a webinar to provide further context to those who would like to participate:

Read More →

Indian Council of Medical Research wins 2017 Kochon Prize

The 2017 Kochon Prize was awarded to the Indian Council of Medical Research for building a tradition of excellence in TB research and development. The 2017 Prize celebrated those who have been pushing scientific boundaries to improve the lives of people affected by TB.

Read More →

New guide to shorter regimen for treating drug-resistant TB

DR-TB STAT + TAG brief: Is Shorter Better? Understanding the Shorter Regimen For Treating Drug-Resistant Tuberculosis

Read More →

Can India eliminate TB by 2025?

New Delhi: The Narendra Modi government is set against major challenges as it looks to achieving its ambitious target of eliminating tuberculosis (TB) by 2025, five years ahead of the global target.

Read More →

Delhi End TB Summit 2018

Ministers and policymakers across the globe call for greater focus on financing and political will to end TB by 2030; PM Modi sets the bar high for the world to End TB.

Read More →

Janssen Pharmaceutica to expand production of Sirturo in Russia

Janssen Pharmaceutica, which is part of US healthcare giant Johnson & Johnson, plans to increase production of its Sirturo (bedaquiline) – an anti-tuberculosis drug – in Russia, at the capacities of a local drugmaker Pharmstandard, according to recent statements of the companies, reports The Pharma Letter’s local correspondent.

Read More →

J&J, Macleods in talks for license deal of TB drug

Mumbai-based Macleods Pharmaceuticals and US drug giant Johnson & Johnson (J&J) are in talks for a voluntary license deal for the TB drug bedaquiline.

Read More →

Indian government negotiating with firms for better access to new TB drugs

The government wants Johnson & Johnson and Mylan to provide treatment for multidrug-resistant TB patients as part of the Revised National Tuberculosis Control Programme.

Read More →

Indian civil society pushes for government use compulsory license on MDR-TB drugs

Advocates appeal to the Prime Minister of India to issue a government use compulsory license for bedaquiline and delamanid to encourage generic competition.

Read More →

Page 1 of 569 · Total posts: 10

1 2 Last→